What was the overall market valuation of the US vertigo treatment market in 2024?

The overall market valuation was $319.2 Million in 2024. Read More

What is the projected market valuation for the US vertigo treatment market by 2035?

The projected valuation for 2035 is $556.6 Million. Read More

What is the expected CAGR for the US vertigo treatment market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 5.18%. Read More

Which types of vertigo conditions are included in the market segments?

The market segments include Benign Paroxysmal Positional Vertigo (BPPV), Labyrinthitis, Vestibular Neuronitis, and Meniere’s disease. Read More

What were the market values for Meniere’s disease in 2024?

The market value for Meniere’s disease was between $129.2 Million and $226.6 Million in 2024. Read More

Which treatment categories are prominent in the US vertigo treatment market?

Prominent treatment categories include Anticholinergics, Antihistamines, Benzodiazepines, and Others. Read More

What was the market value range for Antihistamines in 2024?

The market value range for Antihistamines was between $80.0 Million and $150.0 Million in 2024. Read More

What are the primary end-users in the US vertigo treatment market?

The primary end-users are hospitals and clinics. Read More

What was the market value for hospitals in 2024?

The market value for hospitals was between $159.6 Million and $276.0 Million in 2024. Read More

Which companies are key players in the US vertigo treatment market?

Key players include Bayer AG, Novartis AG, GlaxoSmithKline plc, Sanofi S.A., Merck & Co., Inc., AstraZeneca plc, Pfizer Inc., and Eli Lilly and Company. Read More

US Vertigo Treatment Market

ID: MRFR/HC/18013-HCR 100 Pages Rahul Gotadki Last Updated: September 10, 2026

US Vertigo Treatment Market Research Report By Type (BPPV, Labyrinthitis, Vestibular Neuronitis, Meniere’s disease), By Treatment (Anticholinergics, Antihistamines, Benzodiazepines, Others) and By End User (Hospital, Clinics) - Growth & Industry Forecast 2025 To 2035

US Vertigo Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.18%

2024 Market Size$ 319.2 Million

2025 Market Size$ 335.73 Million

2035 Market Size$ 556.6 Million

Key Players

Bayer AG

Novartis AG

GlaxoSmithKline plc

Sanofi S.A.

Merck & Co.

Inc.

Trends

Technological Advancements in Treatment
Increased Patient Awareness and Education
Expansion of Telehealth Services

Opportunities

Growing Geriatric Population
Advancements in Diagnostic Techniques
Rising Incidence of Vertigo Disorders

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
  1. 4.1.1 Benign Paroxysmal Positional Vertigo (BPPV)
  2. 4.1.2 Labyrinthitis
  3. 4.1.3 Vestibular Neuronitis
  4. 4.1.4 Meniere’s disease
2. 4.2 Industrial Automation & Equipment, BY Treatment (USD Million)
  1. 4.2.1 Anticholinergics
  2. 4.2.2 Antihistamines
  3. 4.2.3 Benzodiazepines
  4. 4.2.4 Others
3. 4.3 Industrial Automation & Equipment, BY End-User (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bayer AG (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis AG (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline plc (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi S.A. (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co., Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca plc (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer Inc. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eli Lilly and Company (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 US MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
8. 6.8 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 (% SHARE)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 TO 2035 (USD Million)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USER, 2024 (% SHARE)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Vertigo Treatment Market Segmentation

US Vertigo Treatment Market By Type (USD Million, 2025-2035)

Benign Paroxysmal Positional Vertigo (BPPV)
Labyrinthitis
Vestibular Neuronitis
Meniere’s disease

US Vertigo Treatment Market By Treatment (USD Million, 2025-2035)

Anticholinergics
Antihistamines
Benzodiazepines
Others

US Vertigo Treatment Market By End-User (USD Million, 2025-2035)

Hospitals
Clinics

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”